BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Teva
Daiichi Sankyo
Novartis
Citi
Federal Trade Commission
Fuji
Chubb
US Army
AstraZeneca
Mallinckrodt

Generated: January 17, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 020600

« Back to Dashboard

NDA 020600 describes TAZORAC, which is a drug marketed by Allergan and is included in two NDAs. It is available from three suppliers. Additional details are available on the TAZORAC profile page.

The generic ingredient in TAZORAC is tazarotene. There are eight drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the tazarotene profile page.
Summary for 020600
Tradename:TAZORAC
Applicant:Allergan
Ingredient:tazarotene
Patents:0
Therapeutic Class:Dermatological Agents
Formulation / Manufacturing:see details
Pharmacology for NDA: 020600
Ingredient-typeRetinoids
Suppliers and Packaging for NDA: 020600
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
TAZORAC tazarotene GEL;TOPICAL 020600 NDA Allergan, Inc. 0023-0042 0023-0042-10 1 TUBE in 1 CARTON (0023-0042-10) > 100 g in 1 TUBE
TAZORAC tazarotene GEL;TOPICAL 020600 NDA Allergan, Inc. 0023-0042 0023-0042-15 15 TUBE in 1 CARTON (0023-0042-15) > 3.5 g in 1 TUBE

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:GEL;TOPICALStrength0.05%
Approval Date:Jun 13, 1997TE:RLD:Yes

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:GEL;TOPICALStrength0.1%
Approval Date:Jun 13, 1997TE:RLD:Yes

Expired US Patents for NDA 020600

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Allergan TAZORAC tazarotene GEL;TOPICAL 020600-002 Jun 13, 1997 ➤ Subscribe ➤ Subscribe
Allergan TAZORAC tazarotene GEL;TOPICAL 020600-001 Jun 13, 1997 ➤ Subscribe ➤ Subscribe
Allergan TAZORAC tazarotene GEL;TOPICAL 020600-001 Jun 13, 1997 ➤ Subscribe ➤ Subscribe
Allergan TAZORAC tazarotene GEL;TOPICAL 020600-002 Jun 13, 1997 ➤ Subscribe ➤ Subscribe
Allergan TAZORAC tazarotene GEL;TOPICAL 020600-002 Jun 13, 1997 ➤ Subscribe ➤ Subscribe
Allergan TAZORAC tazarotene GEL;TOPICAL 020600-001 Jun 13, 1997 ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Dow
Citi
McKesson
Cipla
Covington
Federal Trade Commission
Teva
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot